them, IL-6 is of major importance because of its pleiotropic effects [1] . Here, we presented the evidence that circulating IL-6 levels are closely linked to the severity of COVID-19 infection. An increase in IL-6 levels has previously been observed in patients with respiratory dysfunction [2] , implying a possible shared mechanism of cytokine-mediated lung damage caused by COVID-9
infection. Furthermore, it seems that the highly pathogenic SARS-CoV-2 is associated with rapid virus replication and a tendency to infect the lower respiratory tract, resulting in an elevated response of IL-6-induced severe respiratory distress. Thus, our results suggest that serial measurement of circulating IL-6 levels may be important in identifying disease progression among COVID-19-infected patients. In line with our findings, an elevated level of IL-6 has been proven to be a good biomarker for severity of hepatitis B virus (HBV) infection [10] . Therefore, it is reasonable that immediate initial evaluation of IL-6 level be performed upon hospital admission of COVID-19 patients, due to its potential benefits to assess worsening clinical features and disease progression in COVID-19.
